



# BRCA1/2 mutation spectrum in Chinese early-onset breast cancer

Mengjia Shen<sup>1,2</sup>, Libo Yang<sup>1,2</sup>, Ting Lei<sup>1,2</sup>, Lin Xiao<sup>1</sup>, Li Li<sup>1,3</sup>, Peichuan Zhang<sup>1,3</sup>, Weiyi Feng<sup>4</sup>, Feng Ye<sup>1,3</sup>, Hong Bu<sup>1,2,3</sup>

<sup>1</sup>Laboratory of Pathology, Clinical Research Center for Breast, <sup>2</sup>Department of Pathology, <sup>3</sup>Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu 610041, China; <sup>4</sup>Big Data Research Center, School of Computer Science and Engineering, University of Electronic Science and Technology of China, Chengdu 610054, China

**Contributions:** (I) Conception and design: M Shen, F Ye; (II) Administrative support: H Bu; (III) Provision of study materials or patients: L Xiao, L Li; (IV) Collection and assembly of data: L Yang, T Lei; (V) Data analysis and interpretation: P Zhang, W Feng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Dr. Feng Ye. Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China. Email: fengye@scu.edu.cn.

**Background:** Breast cancer is the most commonly diagnosed cancer among women. Although many studies have reported the *BRCA* mutations among breast cancer patients, few studies have focused among Chinese early-onset breast cancer patients. The purpose of this study is to identify *BRCA1* and *BRCA2* mutation features and their clinical significance of early-onset Chinese breast cancer patients.

**Methods:** A total of 54 female patients diagnosed with breast cancer were enrolled in this study, of which 27 were younger than 40 (study group, mean age 32 years, range, 23–40 years) and 27 were older than 40 (control group, mean age 52 years, range, 41–68 years). Tumor FFPE samples were collected for somatic mutation test, while blood samples or normal tissue were used for germline mutation by both PGM and Miseq platform. All codon exons and functional introns for *BRCA1/2* were covered. The clinical significance of mutation types was cross analyzed in several available database. The novel mutations were confirmed by sanger sequencing.

**Results:** In study group, 14.8% (4/27) and 3.7% (1/27) patients had deleterious *BRCA1/2* germline and somatic mutations respectively. While in control group, only 3.7% (1/27) and 7.4% (2/27) had deleterious *BRCA1/2* germline and somatic mutations respectively. *BRCA1* germline mutation c.2623C>T and *BRCA2* germline mutation c.5852G>A were found to be novel mutation sites and confirmed by sanger sequencing.

**Conclusions:** Our study found two novel *BRCA1/2* mutation sites in early-onset breast cancer, and also showed that early-onset breast cancer patients are more likely to harbor germline mutations with deleterious and uncertain significance.

**Keywords:** *BRCA1*; *BRCA2*; early-onset breast cancer; next-generation sequencing (NGS)

Submitted Nov 28, 2018. Accepted for publication Feb 25, 2019.

doi: 10.21037/tcr.2019.03.02

View this article at: <http://dx.doi.org/10.21037/tcr.2019.03.02>

## Introduction

Breast cancer is the most commonly diagnosed cancer among women and is the second leading cause of cancer death for women in US (1). Early-onset breast cancer, though only accounting for 7% of all breast cancers, is the most common cancer among young females (2), and has been described to be more biologically aggressive than in older women, which has been associated with a

worse prognosis (3). Nowadays, with the development of new techniques, an increasing number of susceptibility gene mutations related to early-onset breast cancer has been detected to improve diagnosis and therapy of early-onset breast cancer and predict outcome. Among all these detected mutations, *BRCA1/2* are still figured out to play an important role in early-onset breast cancer (4-7).

Among the multitude of markers involved into the breast cancer tumorigenesis as *EGFR*, *RANK* (8), *BRCA1*

**Table 1** The characteristics of patients according to the age of diagnosis

Characteristics	Study group (n=27)	Control group (n=27)	P value
Mean age (years)	32	52	<0.001
Estrogen-receptor (ER) status			0.704
Positive	24	22	
Negative	3	5	
Progesterone-receptor (PR) status			0.750
Positive	21	20	
Negative	6	7	
Human epidermal growth factor-2 (HER-2)			0.669
Positive	23	25	
Negative	4	2	
Molecular phenotypes			0.525
Luminal A	1	1	
Luminal B (HER2 <sup>-</sup> )	22	22	
Luminal B (HER2 <sup>+</sup> )	2	0	
HER2 <sup>+</sup>	2	3	
Triple negative	0	1	
TNM stage			
T stage (1 missing)			0.551
Tis	1	0	
T1	8	8	
T2	15	17	
T3	3	1	
T4	0	0	
N stage (1 missing)			0.273
N0	14	14	
N1	9	7	
N2	0	3	
N3	4	2	

and *BRCA2* are the first two genes found directly related to hereditary breast cancer. *BRCA1* is located on 17q21.31, and the exon count is 24. *BRCA2* is located on 13q13.1, and the exon count is 27. Both *BRCA1* and *BRCA2* are considered tumor suppressor gene which involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. Inherited mutations in *BRCA1* and *BRCA2*, confer increased lifetime risk of

developing breast cancer (9). Due to the length of *BRCA1/2*, and the randomness of mutation sites, using the traditional sanger sequencing, qPCR, or MLPA to detect the whole gene is not ideal. In contrast, the high throughput next-generation sequencing (NGS) could be more efficient, that can detect all the exons and their adjacent regions of *BRCA1/2* at a time.

As is mentioned in several published research (10-13), compared with other countries, Chinese women carry different *BRCA* mutations rate and types. In this study, we tried to figure out a detailed *BRCA1/2* germline and somatic mutation spectrum in young Chinese breast cancer patients.

## Methods

### Cases and samples

A total of 54 female patients diagnosed with breast cancer were enrolled in this study, of which 27 patients (mean age 32 years, range, 23–40 years) diagnosed at the age younger than 40 and the rest 27 (mean age 52 years, range, 41–68 years) diagnosed at the age older than 40 in West China Hospital from January 2010 to December 2016 consecutively, belonging to study group and control group, respectively. DNA of 54 FFPE samples of cancer tissue were collected to test the somatic *BRCA1/2* mutations, while DNA of 31 blood samples and 23 FFPE samples of normal tissue were used to exclude the germline *BRCA1/2* mutations by two NGS platforms PGM and Miseq. Clinicopathological characteristics were reviewed including age, estrogen-receptor (ER) status, progesterone-receptor (PR) status, human epidermal growth factor-2 (HER-2) status, Ki-67, molecular phenotypes, TNM staging, etc. Patients' clinical information is showed in *Table 1*. Approval for the study was granted by the Ethics Committee of West China Hospital (number: 2013-191).

### Next generation sequencing on PGM platform and Miseq platform

DNA was extracted using QIAamp DNA FFPE Tissue Kit. For library construction, 30 ng of gDNA (measured using the Qubit fluorometer in combination with the Qubit dsDNA HS assay kit) was amplified using BRCAimPLUS DNA panel (SINGLER Genomics Inc.) and the Ion Ampliseq™ HiFi Master Mix (Ion Ampliseq™ Library kit 2.0). The amplicons were then digested, barcoded and amplified using the Ion Ampliseq™ Library kit 2.0, Ion Xpress™ barcode adapters kit (Life technologies), and

Ion-to-Miseq primers according to the manufacturer's instructions. The library size was checked using the Agilent High Sensitivity DNA Kit by the Bioanalyzer 2100 instrument (Agilent Technologies), and library concentration was evaluated using the Qubit fluorometer and the Qubit dsDNA HS assay kit (Life technologies).

For PGM platform, 50 pM of each library was multiplexed and clonally amplified on the Chef instrument with the Ion PGM™ Hi-Q™ Chef Solutions Cartridge, Ion PGM™ Hi-Q™ Chef Reagents Cartridge, Ion PGM™ Hi-Q™ Chef Supplies and Ion 318™ Chip v2 breast cancer (Life technologies) according to the manufacturer's instructions. Finally, the Ion 318™ chips loaded with enriched template ISP were sequenced on a PGM™ sequencer with the Ion PGM™ sequencing 200 kit v2 according to the manufacturer's instructions.

For Miseq platform, all purified libraries were quantified by real-time PCR using the SYBR Fast Illumina Library Quantification Kit (Kapa Biosystems) and pooled to give equal genome coverage from each library. Each multiplexed library pool was sequenced on an Illumina MiSeq for 151 cycles from each end read according to the manufacturer's instructions.

We then analyzed the sequencing data from both Miseq and PGM platforms using the BRCAimPLUS DNA pipeline—a customized bioinformatic analysis workflow for cancer panel. As other bioinformatic pipelines, it involves processing a series of data transformation steps: alignment, variant calling, annotation, filtering and reporting (14–17).

### Variants confirmation

DNA was extracted using QIAamp DNA FFPE Tissue Kit. PCR reactions were run in final volumes of 25 µL containing 200 ng DNA, 0.25 mM dNTPs, 10pmol of each primer and 1.25 unit of Taq polymerase [TIANGEN BIOTECH (BEIJING) CO., LTD.]. PCR was performed in an T100 thermal cycler (Bio-Rad, Hercules, CA, USA) with initial denaturation at 95 °C for 3 min, followed by 35 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s. The purified PCR products were sequenced by Sanger's sequencing according to manufacturer's instruction.

### Variants evaluation

Variants both detected by two platforms were then to be evaluated. According to the classification system of International Agency for Research on Cancer (IARC), American College of Medical Genetics and Genomics

(ACMG), and Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), the mutations of *BRCA* gene were divided into five categories: pathogenic (Class 5, the rate of pathogenicity is higher than 0.99), likely pathogenic (Class 4, the rate of pathogenicity is between 0.95 and 0.99), uncertain significance (Class 3, the rate of pathogenicity is between 0.05 and 0.949), likely benign (Class 2, the rate of pathogenicity is between 0.001 and 0.049), benign (Class 1, the rate of pathogenicity is lower than 0.001).

Also, the *BRCA* gene variants identified were checked for pathogenicity in 4 databases: Breast Cancer Information Core (BIC) (18), Leiden Open Variation Database (LOVD) (19), the Catalogue of Somatic Mutations in Cancer database (COSMIC) (20) and ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>).

### Statistical analysis

All the statistical analyses were performed using the statistical program for social sciences (SPSS) software package version 19.0 (Chicago, IL, USA). Two independent sample t tests were applied in comparison between groups. Enumeration data was expressed as cases or percentage. Chi-square test was used in comparison between groups, with  $P < 0.05$  represented for the difference was statistically significant.

## Results

### NGS test performance

In the cohort of 54 patients, we obtained an average of 4.1 million reads per sample, with a mean coverage of 90% at a mean X coverage of 2031X on the PGM platform and 5.1 million reads per sample with a mean coverage of 92% at a mean X coverage of 2543X on the Miseq platform. In the early-onset breast cancer patients, 2 had no mutations in *BRCA1/2* genes. In the rest 25 patients, a total of 12 mutations of *BRCA1* were detected by both PGM and Miseq platform in 19 patients (Table 2). Eleven mutations of *BRCA2* gene were detected in 22 patients (Table 3). In control group, two patients had no *BRCA* mutations, while 7 *BRCA1* mutations were detected in 22 patients (Table 2), and 9 *BRCA2* mutations were detected in 22 patients (Table 3).

### Germline *BRCA1/2* mutations detected in young breast cancer patients

In study group, the 11 *BRCA1* germline mutations detected

**Table 2** *BRCA1* gene mutations detected by two platforms

Groups	Exon	Intron	Type	Consequence	cDNA_change	Pro_change	Germline mutation (n)	Somatic mutation (n)
Study group								
<i>BRCA1</i>	–	4/23	SNP	Splice_acceptor_variant	c.213-1G>A	–	0	1
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.988G>A	p.Asp330Asn	1	0
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.1036C>T	p.Pro346Ser	1	0
<i>BRCA1</i>	10/24	–	Indel	Frameshift_variant	c.1299dupC	p.Ser434GlnfsTer2	1	0
<i>BRCA1</i>	10/24	–	SNP	Stop_gained	c.2059C>T	p.Gln687Ter	1	0
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.2566T>C	p.Tyr856His	4	0
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.2612C>T	p.Pro871Leu	14	1
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.2623C>T	p.Pro875Ser	1	0
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.3113A>G	p.Glu1038Gly	14	1
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.3548A>G	p.Lys1183Arg	14	1
<i>BRCA1</i>	15/24	–	SNP	Splice_region_variant&synonymous_variant	c.4674A>G	c.4674A>G (p.Leu1558=)	1	0
<i>BRCA1</i>	16/24	–	SNP	Missense_variant	c.4837A>G	p.Ser1613Gly	15	0
Control group								
<i>BRCA1</i>	7/24	–	SNP	Missense_variant	c.446A>C	p.Glu149Ala	1	0
<i>BRCA1</i>	10/24	–	Indel	Frameshift_variant	c.2398_2401delAAAT	p.Lys800ValfsTer2	0	1
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.2566T>C	10	1	0
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.2612C>T	p.Pro871Leu	16	2
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.3113A>G	p.Glu1038Gly	17	4
<i>BRCA1</i>	10/24	–	SNP	Missense_variant	c.3548A>G	p.Lys1183Arg	17	2
<i>BRCA1</i>	16/24	–	SNP	Missense_variant	c.4837A>G	p.Ser1613Gly	17	3

were classified as following: 2 5-pathogenic, 4 3-uncertain, 5 1-benign, in accordance with the data found in ClinVar (Tables S1,S2). c.2623C>T was identified as novel germline mutation site found in a patient diagnosed as breast cancer at the age of 27 (Figure S1A). Among all, 4 mutations were found to be pending, while the rest were not found in BIC. According to the Leiden Open Variation Database, 2 mutations were definitely indicated to affect function. In COSMIC database, 4 mutations were found to be neutral.

As for *BRCA2*, 10 germline mutations were detected involving 2 5-pathogenic, 3 3-uncertain, 5 1-benign in accordance with the data found in ClinVar (Tables S1,S2). c.5852G>A identified as a novel site found in a patient diagnosed as breast cancer at the age of 28 (Figure S1B).

Among all, 1 mutation c.10234A>G was found to be class 1 in BIC database, 2 mutations were found to be pending, while the rest were not found in BIC. According to the Leiden Open Variation Database, 1 mutation was definitely indicated to affect function. In COSMIC database, 4 mutations were found to be neutral, and 1 referring to be pathogenic.

In control group, there were only 6 *BRCA1* germline in total 27 patients. c.446A>C was a mutation with uncertain significance. c.2566T>C, c.2612C>T, c.3113A>G, c.3548A>G, c.4837A>G were benign mutations. When considered *BRCA2*, 1 pathogenic mutation c.9294C>G, 2 uncertain mutations c.10150C>G, c.3445A>G were identified as well as 5 benign mutations.

**Table 3** *BRCA2* gene mutations detected by two platforms

Groups	Exon	Type	Consequence	cDNA_change	Pro_change	Germline mutation (n)	Somatic mutation (n)
Study group							
<i>BRCA2</i>	27/27	SNP	Missense_variant	c.10234A>G	p.Ile3412Val	0	1
<i>BRCA2</i>	25/27	Indel	Frameshift_variant	c.9401delG	p.Gly3134AlafsTer29	1	0
<i>BRCA2</i>	18/27	SNP	Missense_variant	c.8187G>T	p.Lys2729Asn	1	0
<i>BRCA2</i>	11/27	SNP	Missense_variant	c.5852G>A	p.Ser1951Asn	1	0
<i>BRCA2</i>	11/27	SNP	Missense_variant	c.5785A>G	p.Ile1929Val	1	0
<i>BRCA2</i>	11/27	SNP	Missense_variant	c.2971A>G	p.Asn991Asp	6	0
<i>BRCA2</i>	10/27	SNP	Missense_variant	c.1462A>G	p.Ile488Val	1	0
<i>BRCA2</i>	10/27	SNP	Stop_gained	c.1399A>T	p.Lys467Ter	1	0
<i>BRCA2</i>	10/27	SNP	Missense_variant	c.1114A>C	p.Asn372His	13	1
<i>BRCA2</i>	10/27	SNP	Missense_variant	c.865A>C	p.Asn289His	6	0
<i>BRCA2</i>	5/27	SNP	Missense_variant	c.461A>G	p.Gln154Arg	1	0
Control group							
<i>BRCA2</i>	27/27	SNP	Missense_variant	c.10234A>G	p.Ile3412Val	3	0
<i>BRCA2</i>	27/27	SNP	Missense_variant	c.10150C>G	p.Arg3384Gly	1	0
<i>BRCA2</i>	25/27	SNP	Stop_gained	c.9294C>G	p.Tyr3098Ter	1	0
<i>BRCA2</i>	14/27	Indel	Frameshift_variant	c.7414_7415delAA	p.Lys2472ValfsTer2	0	1
<i>BRCA2</i>	11/27	SNP	Missense_variant	c.5785A>G	p.Ile1929Val	1	0
<i>BRCA2</i>	11/27	SNP	Missense_variant	c.3445A>G	p.Met1149Val	1	0
<i>BRCA2</i>	11/27	SNP	Missense_variant	c.2971A>G	p.Asn991Asp	7	2
<i>BRCA2</i>	10/27	SNP	Missense_variant	c.1114A>C	p.Asn372His	11	6
<i>BRCA2</i>	10/27	SNP	Missense_variant	c.865A>C	p.Asn289His	7	2

### ***Somatic BRCA1/2 mutations detected in young breast cancer patients***

In study group, there were 4 *BRCA1* somatic mutations detected in total, including pathogenic mutation c.213-1G>A and three benign mutation c.2612C>T, c.3113A>G, c.3548A>G only detected in one patient respectively. Also, two *BRCA2* somatic benign mutations c.10234A>G and c.1114A>C were detected.

In control group, 5 *BRCA1* somatic mutations involving pathogenic mutation c.2398\_2401delAAAT detected in one patient, and four benign mutations c.2612C>T, c.3548A>G, c.4837A>G, c.3113A>G. Also, 4 *BRCA2* somatic mutations were detected, of which c.7414\_7415delAA was pathogenic with the rest c.2971A>G, c.865A>C, and c.1114A>C turned out to be benign.

### ***BRCA1/2 mutations of pathogenic and uncertain significance in young breast cancer patients***

Mutations defined as pathogenic/likely pathogenic and uncertain were selected for further analysis, as is shown in *Table 4*. In total, 11 germline (7 3-uncertain, 4 5-pathogenic) and 1 somatic (5-pathogenic) of *BRCA1/2* mutations were detected in study group, while 4 germline (3 3-uncertain and 1 5-pathogenic) and 2 somatic (2 5-pathogenic) of *BRCA1/2* mutations were detected in control group.

In study group, 14.8% (4/27) and 3.7% (1/27) patients had deleterious *BRCA1/2* germline and somatic mutations respectively. While in control group, only 3.7% (1/27) and 7.4% (2/27) had deleterious *BRCA1/2* germline and somatic mutations, respectively.

**Table 4** The distribution of 3-uncertain and deleterious *BRCA1/2* mutations in two groups

Groups	Variations	Clinical significance	Germline mutations (n)	Somatic mutations (n)
Study group				
<i>BRCA1</i>	c.988G>A	3-uncertain	1	0
<i>BRCA1</i>	c.4674A>G	3-uncertain	1	0
<i>BRCA1</i>	c.1036C>T	3-uncertain	1	0
<i>BRCA1</i>	c.2623C>T	3-uncertain	1	0
<i>BRCA1</i>	c.2059C>T	5-pathogenic	1	0
<i>BRCA1</i>	c.1299dupC	5-pathogenic	1	0
<i>BRCA1</i>	c.213-1G>A	5-pathogenic	0	1
<i>BRCA2</i>	c.1462A>G	3-uncertain	1	0
<i>BRCA2</i>	c.461A>G	3-uncertain	1	0
<i>BRCA2</i>	c.5852G>A	3-uncertain	1	0
<i>BRCA2</i>	c.9401delG	5-pathogenic	1	0
<i>BRCA2</i>	c.1399A>T	5-pathogenic	1	0
Control group				
<i>BRCA1</i>	c.446A>C	3-uncertain	1	0
<i>BRCA1</i>	c.2398_2401delAAAT	5-pathogenic	0	1
<i>BRCA2</i>	c.10150C>G	3-uncertain	1	0
<i>BRCA2</i>	c.3445A>G	3-uncertain	1	0
<i>BRCA2</i>	c.9294C>G	5-pathogenic	1	0
<i>BRCA2</i>	c.7414_7415delAA	5-pathogenic	0	1

The 4 pathogenic germline mutations were c.2059C>T, c.1299dupC, c.9401delG, c.1399A>T found in study group at the age of 40, 28, 36, 40. And 7 uncertain germline mutations existed in study group were c.988G>A, c.4674A>G, c.1036C>T, c.2623C>T, c.1462A>G, c.461A>G, c.5852G>A. When it turns to control group, there was only one pathogenic germline mutation c.9294C>G found in patient at the age of 57 and 3 uncertain germline mutations c.446A>C, c.10150C>G, c.3445A>G.

## Discussion

*BRCA* status is not only important for the identification of familial cancer predisposition but also to therapeutic choices for breast cancer patients, e.g., the PARP inhibitor therapy (21-23). *BRCA* gene mutation is closely related to the early-onset breast cancer occurrence. In most national and international guidelines, testing criteria of *BRCA* includes patients with breast cancer aged less than 35 or 40 years (24). *BRCA1/2* mutation carriers diagnosed with breast cancer

before age 50 are prone to a worse survival (25). In our study, the mean age of 27 early-age onset breast cancer patients was 32, with the minimum hospitalized age 23. Only 2 had no *BRCA1/2* mutation. Twenty patients had *BRCA1* mutations and 22 had *BRCA2* mutations, with 3 (11.1%) patients had pathogenic mutations involving c.1299dupC, c.2059C>T, c.213-1G>A in *BRCA1/2* (7.4%) had pathogenic mutations involving c.9401delG, c.1399A>T in *BRCA2*, which were not found in control group. The mutation frequency of the deleterious germline mutation in our study is a little bit higher than in other research (24,26,27) may attribute to insufficient number of analyzed cases.

*BRCA1* mutation c.2623C>T was identified as a germline mutation for the first time in this study, which was a SNP detected in EXON10 leading to the protein change p.Pro875Ser. The patient who had c.2623C>T mutation as the only *BRCA* mutation diagnosed as breast cancer at the age of 27. As for *BRCA2*, c.5852G>A was also identified as a germline mutation for the first time in this study which was a SNP detected in EXON11 leading to the protein change

p.Ser1951Asn. The patient who had c.5852G>A mutation as the only *BRCA* mutation other than benign mutations diagnosed as breast cancer at the age of 28. Since these two new mutation sites were detected in patients at such young age without other suspicious *BRCA* mutation sites, we have reason to suspect that these two mutation sites may play a role in the pathogenesis of the early-onset breast cancer which need to be further confirmed.

A large number of literatures show strong correlation between *BRCA* mutation and familial early-onset breast cancer (28-30). In our study, in total, 11 germline (7 3-uncertain, 4 5-pathogenic) and 1 somatic (5-pathogenic) of *BRCA1/2* mutations were detected in study group, while 4 germline (3 3-uncertain and 1 5-pathogenic) and 2 somatic (2 5-pathogenic) of *BRCA1/2* mutations were detected in control group. In study group, 14.8% (4/27) patients had deleterious *BRCA1/2* germline mutations, and 3.7% (1/27) had deleterious *BRCA1/2* somatic mutations, while in control group, 3.7% (1/27) had deleterious *BRCA1/2* germline mutations, and 7.4% (2/27) had deleterious *BRCA1/2* somatic mutations, displaying a trend that early-onset group is more likely to have germline mutations than elderly counterparts. Therefore, there is a strong recommendation for the early-onset breast cancer patients despite of the family history to get *BRCA* test for potential benefit for their family members as well as benefit for the patient of PARP inhibitor therapy.

One of the limitations of the study is the absence of triple negative samples in the study groups which is among the breast cancer histotypes the more aggressive with the poor prognosis caused by insufficient cases, but we tried to figure out a detailed spectrum of *BRCA1/2* germline and somatic mutations of early-onset breast cancer patients in West China Hospital using NGS. Several deleterious and uncertain mutations were observed in this cohort and it is recommended that a more thorough and functional examination of these mutations should be conducted in the future.

### Acknowledgments

*Funding:* This work was supported by the Development Project of Department of Science & Technology in Sichuan Province (2018JY0277) and Research Project from Health Commission of Sichuan Province (16PJ335).

### Footnote

*Conflicts of Interest:* All authors have completed the ICMJE

uniform disclosure form (available at <http://dx.doi.org/10.21037/tcr.2019.03.02>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Approval for the study was granted by the Ethics Committee of West China Hospital (number: 2013-191). And the study was done with all patients' informed consent.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

### References

1. DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. *CA Cancer J Clin* 2017;67:439-48.
2. Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. *Semin Oncol* 2009;36:237-49.
3. Bonnier P, Romain S, Charpin C, et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. *Int J Cancer* 1995;62:138-44.
4. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117-30.
5. Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. *Breast Cancer Res* 2012;14:R66.
6. Moghadasi S, Eccles DM, Devilee P, et al. Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes. *Hum Mutat* 2016;37:331-6.

7. Torrezan GT, de Almeida FGDSR, Figueiredo MCP, et al. Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer. *Front Genet* 2018;9:161.
8. Mercatali L, La Manna F, Miserocchi G, et al. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. *Int J Mol Sci* 2017;18:E1655.
9. Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. *Breast Cancer Res* 2006;8:R12.
10. Cao W, Wang X, Li JC. Hereditary breast cancer in the Han Chinese population. *J Epidemiol* 2013;23:75-84.
11. Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. *Int J Cancer* 2017;141:129-42.
12. Li G, Guo X, Tang L, et al. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing. *J Cancer Res Clin Oncol* 2017;143:2011-24.
13. Kwong A, Ho JCW, Shin VY, et al. Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. *Oncotarget* 2017;9:7832-43.
14. Li B, Krishnan VG, Mort ME, et al. Automated inference of molecular mechanisms of disease from amino acid substitutions. *Bioinformatics* 2009;25:2744-50.
15. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 2010;26:589-95.
16. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297-303.
17. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011;43:491-8.
18. Szabo C, Masiello A, Ryan JF, et al. The breast cancer information core: database design, structure, and scope. *Hum Mutat* 2000;16:123-31.
19. Fokkema IF, Taschner PE, Schaafsma GC, et al. LOVD v.2.0: the next generation in gene variant databases. *Hum Mutat* 2011;32:557-63.
20. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res* 2015;43:D805-11.
21. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 2010;376:235-44.
22. Plummer R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? *Breast Cancer Res* 2011;13:218.
23. Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treat* 2014;147:401-5.
24. Fasching PA. Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? *Lancet Oncol* 2018;19:150-1.
25. Schmidt MK, van den Broek AJ, Tollenaar RA, et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. *J Natl Cancer Inst* 2017;109:djw329.
26. Son BH, Ahn SH, Kim SW, et al. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study. *Breast Cancer Res Treat* 2012;133:1143-52.
27. Zugazagoitia J, Perez-Segura P, Manzano A, et al. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. *Breast Cancer Res Treat* 2014;148:415-21.
28. Loman N, Johannsson O, Kristoffersson U, et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. *J Natl Cancer Inst* 2001;93:1215-23.
29. Semple J, Metcalfe KA, Lubinski J, et al. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? *Breast Cancer Res Treat* 2015;154:163-9.
30. Azzollini J, Scuvera G, Bruno E, et al. Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. *Eur J Intern Med* 2016;32:65-71.

**Cite this article as:** Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P, Feng W, Ye F, Bu H. *BRCA1/2* mutation spectrum in Chinese early-onset breast cancer. *Transl Cancer Res* 2019;8(2):483-490. doi: 10.21037/tcr.2019.03.02



## Supplementary

**Table S1** *BRCA1* variations found and their evaluations in BRCA databases


Variations	Clinical significance	BIC database clinically importance/clinical classification	LOVD	COSMIC	ClinVar
Study group					
c.213-1G>A	5-pathogenic	Pending	Affects function	Not found	Pathogenic
c.988G>A	3-uncertain	Not found	Not found	Not found	Uncertain significance
c.4674A>G	3-uncertain	Not found	Effect unknown	Not found	Uncertain significance
c.1299dupC	5-pathogenic	Not found	Not found	Not found	Pathogenic
c.2623C>T	3-uncertain	Not found	Not found	Not found	Not found
c.1036C>T	3-uncertain	Pending	Effect unknown; affects function	Not found	Conflicting interpretations of pathogenicity
c.2059C>T	5-pathogenic	Not found	Affects function	Not found	Pathogenic
c.2566T>C	1-benign	Pending	Does not affect function	Not found	Benign
c.2612C>T	1-benign	Not found	Does not affect function	Neutral	Benign
c.3113A>G	1-benign	Not found	Does not affect function	Neutral	Benign
c.3548A>G	1-benign	Pending	Does not affect function	Neutral	Benign
c.4837A>G	1-benign	Pending	Does not affect function	Neutral	Benign
Control group					
c.446A>C	3-uncertain	Not found	Not found	Not found	Uncertain significance
c.2398_2401delAAAT	5-pathogenic	Not found	Not found	Not found	Pathogenic
c.2566T>C	1-benign	Pending	Does not affect function	Not found	Benign
c.2612C>T	1-benign	Not found	Does not affect function	Neutral	Benign
c.3113A>G	1-benign	Not found	Does not affect function	Neutral	Benign
c.3548A>G	1-benign	Pending	Does not affect function	Neutral	Benign
c.4837A>G	1-benign	Pending	Does not affect function	Neutral	Benign

BIC, Breast Cancer Information Core; LOVD, Leiden Open Variation Database; COSMIC, Catalogue of Somatic Mutations in Cancer database.

**Table S2** *BRCA2* variations found and their evaluations in BRCA databases

Variations	Clinical significance	BIC database clinically importance/ clinical classification	LOVD	COSMIC	ClinVar
Study group					
c.9401delG	5-pathogenic	Not found	Not found	Not found	Pathogenic
c.8187G>T	1-benign	Pending	Does not affect function	Pathogenic	Benign
c.5852G>A	3-uncertain	Not found	Not found	Not found	Not found
c.1462A>G	3-uncertain	Not found	Not found	Not found	Conflicting interpretations of pathogenicity
c.1399A>T	5-pathogenic	Not found	Affects function	Not found	Pathogenic
c.461A>G	3-uncertain	Not found	Not found	Not found	Uncertain significance
c.10234A>G	1-benign	Class 1	Does not affect function	Neutral	Benign
c.5785A>G	1-benign	Pending	Does not affect function; Effect unknown	Not found	Benign
c.2971A>G	1-benign	Not found	Does not affect function	Neutral	Benign
c.1114A>C	1-benign	Not found	Does not affect function	Neutral	Benign
c.865A>C	1-benign	Not found	Does not affect function	Neutral	Benign
Control group					
c.10150C>G	3-uncertain	Not found	Not found	Not found	Uncertain significance
c.9294C>G	5-pathogenic	Class 5	Affects function	Not found	Pathogenic
c.7414_7415delAA	5-pathogenic	Not found	Not found	Not found	Pathogenic
c.3445A>G	3-uncertain	Pending	Effect unknown	Not found	Conflicting interpretations of pathogenicity
c.10234A>G	1-benign	Class 1	Does not affect function	Neutral	Benign
c.5785A>G	1-benign	Pending	Does not affect function; Effect unknown	Not found	Benign
c.2971A>G	1-benign	Not found	Does not affect function	Neutral	Benign
c.1114A>C	1-benign	Not found	Does not affect function	Neutral	Benign
c.865A>C	1-benign	Not found	Does not affect function	Neutral	Benign

BIC, Breast Cancer Information Core; LOVD, Leiden Open Variation Database; COSMIC, Catalogue of Somatic Mutations in Cancer database.



**Figure S1** Sanger sequence of two novel mutation sites. (A) The position indicated by the arrows show the mutation site c.2623C>T. The figure above shows the sequencing result of tumor tissue, while the lower figure shows the result of normal tissue. (B) Arrows indicate the mutation site c.5852G>A. The figure above shows the sequencing result of tumor tissue, while the lower figure shows the result of normal tissue.